Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023)
Pyxis Oncology (PYXS) reported Receivables - Other of $21000.0 for Q4 2023, down 96.49% year-over-year from $598000.0 in Q4 2022, and down 96.49% quarter-over-quarter from $598000.0 in Q4 2022.
Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of Receivables - Other data on file, last reported at $21000.0 in Q4 2023.
- Receivables - Other for Q4 2023 came in at $21000.0, down 96.49% year-over-year; the trailing twelve-month figure through Dec 2023 was $21000.0 (down 96.49% YoY), and the FY2023 annual result was $21000.0, down 96.49% from the prior year.
- Receivables - Other slipped to $21000.0 in Q4 2023 per PYXS's latest filing, from $598000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $598000.0 in Q4 2022 and troughed at $21000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2022 | 598,000.00 |
| Dec 31, 2022 | 598,000.00 |